Literature DB >> 9809976

The role for NES1 serine protease as a novel tumor suppressor.

J Goyal1, K M Smith, J M Cowan, D E Wazer, S W Lee, V Band.   

Abstract

Previously (Liu et al, Cancer Res., 56: 3371-3379, 1996), we isolated a novel serine protease-like gene--Normal Epithelial Cell Specific-1 (NES1)--that is expressed in normal mammary epithelial cells but is down-regulated in most breast cancer cell lines. Here, we demonstrate that stable expression of NES1 in the NES1-negative MDA-MB-231 breast cancer cell line suppressed the oncogenicity as revealed by inhibition of the anchorage-independent growth and tumor formation in nude mice. Fluorescence in situ hybridization localized the NES1 gene to chromosome 19q13.3, a region that contains genes for related proteases (including the prostate-specific antigen) and is rearranged in human cancers. Similar to breast cancer cell lines, prostate cancer cell lines also lacked NES1 mRNA and protein expression. Together, these results strongly suggest a tumor-suppressor role for NES1 in breast and prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809976

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Authors:  Julien Laffaire; Sibille Everhard; Ahmed Idbaih; Emmanuelle Crinière; Yannick Marie; Aurelien de Reyniès; Renaud Schiappa; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Joëlle Thillet; François Ducray
Journal:  Neuro Oncol       Date:  2010-10-05       Impact factor: 12.300

Review 2.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

3.  Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer.

Authors:  Chunmei Wang; Luciana P Schwab; Meiyun Fan; Tiffany N Seagroves; John K Buolamwini
Journal:  Cancer Prev Res (Phila)       Date:  2013-02-27

4.  NES1/KLK10 and hNIS gene therapy enhanced iodine-131 internal radiation in PC3 proliferation inhibition.

Authors:  Jiajia Hu; Wenbin Shen; Qian Qu; Xiaochun Fei; Ying Miao; Xinyun Huang; Jiajun Liu; Yingli Wu; Biao Li
Journal:  Front Med       Date:  2019-05-22       Impact factor: 4.592

5.  Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer.

Authors:  Maroulio Talieri; Dimitra K Alexopoulou; Andreas Scorilas; Dimitris Kypraios; Niki Arnogiannaki; Marina Devetzi; Matina Patsavela; Dimitris Xynopoulos
Journal:  Tumour Biol       Date:  2011-04-12

6.  Screening and analysis of breast cancer genes regulated by the human mammary microenvironment in a humanized mouse model.

Authors:  Mingjie Zheng; Jue Wang; Lijun Ling; Dandan Xue; Shui Wang; Yi Zhao
Journal:  Oncol Lett       Date:  2016-10-24       Impact factor: 2.967

7.  Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.

Authors:  Ekaterina Olkhov-Mitsel; Theodorus Van der Kwast; Ken J Kron; Hilmi Ozcelik; Laurent Briollais; Christine Massey; Franz Recker; Maciej Kwiatkowski; Neil E Fleshner; Eleftherios P Diamandis; Alexandre R Zlotta; Bharati Bapat
Journal:  Epigenetics       Date:  2012-08-09       Impact factor: 4.528

8.  The canine kallikrein-related peptidases 9 and 10: structural characterization and expression in mammary cancer.

Authors:  Katerina Angelopoulou; George S Karagiannis
Journal:  Mamm Genome       Date:  2009-12-02       Impact factor: 2.957

9.  Smad signaling is required to maintain epigenetic silencing during breast cancer progression.

Authors:  Panagiotis Papageorgis; Arthur W Lambert; Sait Ozturk; Fangming Gao; Hongjie Pan; Upender Manne; Yuriy O Alekseyev; Arunthathi Thiagalingam; Hamid M Abdolmaleky; Marc Lenburg; Sam Thiagalingam
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

Review 10.  Epigenetic targeting in breast cancer: therapeutic impact and future direction.

Authors:  M B Lustberg; B Ramaswamy
Journal:  Drug News Perspect       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.